PatientsVille.com Logo

Bladder cancer and Amaryl

PatientsVille

Bladder Cancer Symptoms and Causes

The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States.

Symptoms include

  • Blood in your urine
  • A frequent urge to urinate
  • Pain when you urinate
  • Low back pain

Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk.

Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer.

NIH: National Cancer Institute

Check out the latest treatments for bladder cancer

bladder cancer treatment research studies

Amaryl clinical trials, surveys and public health registries


Find Drug Side Effect reports



Amaryl Side Effects

Hypoglycaemia (149)
Hypoglycaemic Coma (74)
Blood Glucose Increased (52)
Hyperglycaemia (41)
Myocardial Infarction (38)
Renal Failure Acute (36)
Loss Of Consciousness (30)
Blood Creatine Phosphokinase Increased (30)
Depressed Level Of Consciousness (29)
Cardiac Failure Congestive (28)
Diarrhoea (28)
Cerebrovascular Accident (28)
Nausea (28)
Fall (28)
Renal Failure (27)
Coronary Artery Disease (27)
Malaise (25)
Cardiac Failure (23)
Dyspnoea (23)
Rhabdomyolysis (23)
Coma (22)
Vomiting (21)
Diabetes Mellitus Inadequate Control (20)
Dizziness (20)
Altered State Of Consciousness (19)
Oedema Peripheral (19)
Glycosylated Haemoglobin Increased (19)
Hypertension (18)
Death (18)
Hyperkalaemia (18)
Confusional State (17)
Blood Creatinine Increased (17)
Asthenia (16)
Fatigue (16)
Pneumonia (16)
Somnolence (16)
Renal Impairment (16)
Hypoglycaemic Encephalopathy (15)
Syncope (15)
Pyrexia (14)
Bladder Cancer (14)
Blood Potassium Increased (14)
Hepatic Function Abnormal (14)
Lactic Acidosis (14)
Cardio-respiratory Arrest (13)
Blood Glucose Decreased (13)
Chest Pain (13)
Weight Decreased (13)
Interstitial Lung Disease (13)
Convulsion (13)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I am a diabetic peson,recently I am seeing this unsual skin rashes all over my body particularly in my stomach and arms, wanted to know is it because of amarly or because of the pumpkin nuts that I am eating. I would highly appreciate a quick reply i

Inadequate control of blood sugar, have to starve myself to get lower blood sugar even on two types of insulin, diarrhoea, dizziness, syncope, dyspnoea, severe malaise, nausea, tremors.

Mum passed away from bladder/bowel cancer, now I have lower back and abdominal pain

MY MOM IS 82 AND HAS BLADDER CANCER TREATMENTS FOR SEVERAL YEARS OFF AND ON,NOW SHE EXPERIENCES PAIN IN HER BLADDER WHEN SHE URINATES,HAD MUTIPLE CHECKS FOR INFECTION,BUT NONE IS PRESENT,I NEED HELP TO HEPLP EDUCATE HER,SHE JUST WANTS TO GIVE UP SOME

<strong>I was put on Metoprolol ER 2 years ago after having cancer. I was </strong><span style='text-decoration: underline;'>tired all day could not sleep at night, had anxiety attacks, co

1 day off the start of week 3 from day one my dreams have been crazy intense colourful wonderuss things, not stopped smoking yet although i'm not enjoying the dreaded cancer sticks....................... joking aside i have this careless attitude

4 years old boy ,liver cancer ,liver transplant . Is going to start Sorafenib . Is there any kids that got this treatment ?

48YO male, obese, diabetic, hypertensive, mild anxiety and depression. R BKA, R Acetabula fracture 13 years ago from motorcycle accident. Swollen gall bladder removed during hospitalization. Current meds include Metformin (withheld pre- and post- ct)

52years old went on kliovance 1mg, felt great on the tables no hot flushes no weight gain feeling pretty good.Now 53 l have lung cancer dont know if it is related or not,l have never smoked in my life.l had the cancer remove and hope for the best.but

A friend of mine has cancer and the doctors are talking about having surgery and removing the sciatica nerve. My question is will he be a function with this removal.

Afer five years of Famera treatment for breast cancer, I was anticipating feeling so much better. Now diagnosed with CFS and Fibromyalgia my doctor is trying to treat me lately with Chronic Behavorial Therapy. Yesterday my daughter took me to another

After being put on this for Bladder Infection..I experience lip swelling about 3 days in. It was not terrible but uncomfortable. I had NO other signs of anything else. If you pulled up and down my lips you could also see some red. I stopped taking af

After taking raptiva for about 1.5 years i developed pancreatic cancer. Half of my pancreas and all of my spleen was removed as a result I now have dibetes

Age 58, stage 1 breast cancer a year ago. double mastecomy, by choice. chemo...started aromasin in October 2008. had a bone denstity test in September 2008 and started fosamax.... had another bone denstity test in April 2009 and before the results

Bladder Cancer Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepiride;   Drug: glargine and metformin
Outcome Measures: 24 weeks after treatment, HbA1c values' change compared with baseline;   hypoglycemia events
2 Recruiting Study of the Durability of Glycemic Control With Nateglinide
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Nateglinide;   Drug: Glimepiride
Outcome Measures: The durability of nateglinide in comparison with those of glimepiride based on the withdrawal rate;   1. HbA1c, Fasting blood sugar, 2hours postprandial blood sugar 2. insulin secretion(C-peptide), insulin sensitivity(HOMA-IR), lipid profile
3 Not yet recruiting Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Gemigliptin/Glimepiride combination
Outcome Measure: HbA1c Changes
4 Recruiting MK-8835/PF-04971729 vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin;   Drug: Glimepiride;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Glimepiride;   Drug: Metformin;   Drug: Sitagliptin
Outcome Measures: Change from Baseline in Hemoglobin A1C at Week 52;   Number of Participants Experiencing An Adverse Event (AE);   Number of Participants Discontinuing Study Treatment Due to an AE;   Number of Participants with an Adverse Event of Symptomatic Hypoglycemia;   Change from Baseline in Body Weight at Week 52;   Change from Baseline in Systolic Blood Pressure at Week 52
5 Recruiting Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
Conditions: Type 2 Diabetes;   Hypoglycemia
Interventions: Drug: vildagliptin and metformin (combination);   Drug: glimepiride;   Drug: Metformin
Outcome Measures: glycemic variability measured by Mean Amplitude of Average Glucose Excursions (MAGE);   glycemic variability measured by Continuous Overlapping Net Glycemic Action (CONGA);   Percentage of patients who achieve a decrease equal to or greater than 0.3% in value of HbA1c at week 12 of treatment in comparison to HbA1c value at screening visit;   Percentage of reduction achieved in the mean HbA1c at week 12 of treatment in comparison to HbA1c at screening visit;   Degree of correlation between MAGE value and hypoglycemia incidence;   percentage of patients with incidence of hypoglycemia;   Glycemic variability measured by Total Standard Deviation (TSD);   Number of patients with adverse events, serious adverse events and death
6 Recruiting Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin;   Drug: Glimepiride;   Drug: Metformin
Outcome Measures: Mean amplitude of glycemic excursions (MAGE) using continuous glucose monitoring system (CGMS);   Percent glycosylated hemoglobin reduction from baseline at 16 weeks;   Time to glycemic control assessed through CGMS;   Percentage of patients reaching the glycemic targets after 16 weeks treatment, in the overall study population;   Number of unrecognized hypoglycemia events recognized by CGMS;   Number of patients with adverse events, serious adverse events and death
7 Recruiting Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes
Conditions: Type 2 Diabetes;   Cardiovascular Disease
Interventions: Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Placebo
Outcome Measures: One primary outcome will be change in peak oxygen consumption (VO2peak).;   Changes from baseline in 31P measurement: phosphocreatine;   One primary outcome will be oxygen uptake kinetics (VO2 kinetics);   Changes from baseline in 31P measurement: free Pi;   Changes from baseline in 31P measurement: adenosine triphosphate (ATP) peaks;   Changes from baseline in 31P measurement: adenosine diphosphate (ADP);   Changes from baseline in 31P measurement: pH;   Changes from baseline in echocardiographic measures;   Change from baseline in peak dilation of brachial artery diameter;   Change in (non-invasively measured) deoxygenated hemoglobin concentration in the vastus lateralis during exercise
8 Unknown  Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Linagliptin;   Drug: Glimepiride
Outcome Measures: Postprandial increase in intact Proinsulin levels (Peak, AUC);   Postprandial Proinsulin/Insulin Ratio;   Fasting intact Proinsulin levels;   Fasting Proinsulin/Insulin Ratio;   Fasting Blood Glucose;   Postprandial Blood Glucose Excursions (Peak; AUC);   Fasting Lipids;   Postprandial Lipids;   Fasting Erythrocyte Flexibility;   Postprandial Erythrocyte Flexibility;   Fasting GLP-1 levels;   Postprandial GLP-1 levels;   Fasting cGMP;   Postprandial cGMP;   Fasting Calcitonin;   Fasting PAI-1 levels;   Postprandial PAI-1 levels;   Fasting ADMA levels;   Postprandial ADMA levels;   Fasting Malonyldialdehyd;   fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo;   Hypoglycemic events;   Body Weight
9 Recruiting START-J: SiTAgliptin in eldeRly Trial in Japan
Condition: Type 2 Diabetes
Intervention: Drug: Sitagliptin, Glimepiride
Outcome Measures: HbA1c change from baseline as efficacy and incidence of hypoglycaemia as safety;   Comparison between two groups in the following parameters at 52W as well as 24 W as interim analysis
10 Recruiting A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo to Ertugliflozin;   Other: Glimepiride;   Drug: Placebo to Glimepiride;   Biological: Basal Insulin;   Drug: Metformin
Outcome Measures: Change from Baseline in Hemoglobin A1c;   Number of Participants Experiencing An Adverse Event (AE);   Number of Participants Discontinuing Study Treatment Due to an AE;   Change from Baseline in Fasting Plasma Glucose;   Change from Baseline in Body Weight at Week 26;   Number of participants with a HbA1c of <7% (53 mmol/mol) at Week 26;   Change from Baseline in Systolic Blood Pressure;   Change from Baseline in Diastolic Blood Pressure;   Change from Baseline in Bone Mineral Density at Week 26;   Change from Baseline in Bone Mineral Density at Week 52;   Change from Baseline in Bone Mineral Density at Week 104;   Number of participants with HbA1c <=6.5% (48 mmol/mol) at Week 26;   Number of participants requiring glycemic rescue therapy up to Week 26;   Time to glycemic rescue therapy up to Week 26;   Change from baseline in bone biomarkers at Week 26;   Change from baseline in bone biomarkers at Week 52;   Change from baseline in bone biomarkers at Week 104
11 Recruiting Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on MAGE in Patients With Type 2 DM
Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin
Outcome Measures: Mean Amplitude Glycemic Excursion;   Glucagon;   Active GLP-1;   CRP;   Nitrotyrosine;   Glycated albumin;   Fructosamine
12 Recruiting Effects of Vildagliptine and Glimepiride on Glucose Variability
Condition: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Drug: Glimepiride;   Drug: Vildagliptin
Outcome Measures: Glycemic variability index;   Cardiovascular disease risk factor;   glucose profile and lipid profile;   hypoglycemic index
13 Recruiting Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"
Condition: Type 2 Diabetes
Interventions: Drug: Sitagliptin;   Drug: Saxagliptin;   Drug: Glimepiride;   Drug: Blank control
Outcome Measures: The acute phase and second phase of insulin secretion and C peptide secretion;   Alpha cell function,GLP-1 response
14 Recruiting Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Drug: Linagliptin 5 mg QD;   Drug: Glimepiride 1 mg QD
Outcome Measures: Changes from baseline following 8-week treatment with a DPP-4i versus SU derivative on renal hemodynamics, measured as Glomerular Filtration Rate / Effective Renal Plasma Flow (determined by the combined inulin/para-aminohippuric-acid clearance method);   Renal tubular function;   Renal damage, measured by urine biomarkers;   Blood Pressure and Heart Rate
15 Recruiting Liraglutide and Heart Failure in Type 2 Diabetes
Conditions: Congestive Heart Failure;   Type 2 Diabetes Mellitus
Interventions: Drug: liraglutide;   Drug: glimepiride;   Drug: Metformin
Outcome Measures: Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography;   24-hour blood pressure;   Energy delivering from the carotid artery;   N-terminal pro b-type natriuretic peptide (NT-proBNP) levels in serum over time and symptoms of dyspnea or fatigue as assessed by patient and clinician using established scoring systems;   Gene and protein expression (Affymetrix/proteomics);   Plasma markers of inflammation i.e. hsCRP, IL-6, TNF-α and PAI-1;   Plasma markers of endothelial activation i.e. E-selectin, VCAM-1, ICAM-1 and plasma levels of nitrate/nitrite;   Lipids;   A1c;   Body weight;   Adverse events in terms of hypoglycaemia;   Quality of life (SF 36);   Exercise ECG, including working capacity;   Global LV function (echocardiography) expressed as ejection fraction (EF)
16 Unknown  Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Condition: Diabetes Mellitus Type II
Interventions: Drug: Metformin;   Drug: Vildagliptin;   Drug: Glimepiride
Outcome Measures: Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min);   Fasting intact proinsulin levels;   Max postprandial intact proinsulin levels;   Retinal endothelial response to flicker light stimulation;   Mean 24h systolic and diastolic blood pressure;   Erythrocyte deformability;   E-selectin;   Change in body weight;   hsCRP;   HbA1c;   Fasting blood glucose;   Number of hypoglycemic events;   Adverse events;   Drug related adverse events
17 Recruiting Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Outcome Measures: Change from baseline in hemoglobin A1C at Week 26;   Number of Participants Experiencing An Adverse Event (AE);   Number of Participants Discontinuing Study Treatment Due to an AE;   Change from baseline in fasting plasma glucose (FPG) at Week 26;   Change from baseline in body weight at Week 26;   Number of participants with an A1C <7% (53 mmol/mol) at Week 26;   Change from baseline in systolic blood pressure at Week 26
18 Unknown  Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress
Condition: Type 2 Diabetes
Interventions: Drug: Sitagliptin;   Drug: Glimepiride
Outcome Measures: Glucose variability;   oxidative stress markers (oxidized LDL, N-carboxymethyl-lysine(CML), nitrotyrosine, 8-iso-prostaglandinF2α, 8-OhDG)
19 Recruiting Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Outcome Measures: Change from Baseline in A1C;   Number of Participants Who Experience an Adverse Event (AE);   Number of Participants Who Discontinue Study Medication due to an AE;   Change from Baseline in Body Weight;   Change from Baseline in Fasting Plasma Glucose;   Change from Baseline in Systolic Blood Pressure;   Percentage of Participants Achieving a Hemoglobin A1C of <7%;   Change from Baseline in Parameters of Beta-cell Function
20 Recruiting A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
Conditions: Type 2 Diabetes;   Comparative Effectiveness of Glycemia-lowering Medications
Interventions: Drug: Sulfonylurea (glimepiride);   Drug: DPP-4 inhibitor (sitagliptin);   Drug: GLP-1 receptor agonist (liraglutide);   Drug: Insulin (glargine)
Outcome Measures: Time to HbA1c>=7%, while receiving metformin and the randomly assigned study medication;   Time to HbA1c>7.5%, while receiving metformin and the randomly assigned study medication.